NasdaqGS:SNDX

Stock Analysis Report

Executive Summary

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Snowflake

Fundamentals

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Syndax Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.2%

SNDX

1.7%

US Biotechs

1.3%

US Market


1 Year Return

-9.3%

SNDX

-8.8%

US Biotechs

5.9%

US Market

Return vs Industry: SNDX matched the US Biotechs industry which returned -8.8% over the past year.

Return vs Market: SNDX underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

SNDXIndustryMarket
7 Day3.2%1.7%1.3%
30 Day-27.4%-3.5%-1.9%
90 Day-30.6%-3.1%-1.8%
1 Year-9.3%-9.3%-8.0%-8.8%8.3%5.9%
3 Year-56.9%-56.9%13.9%9.9%45.6%36.2%
5 Yearn/a3.8%-1.2%66.1%47.9%

Price Volatility Vs. Market

How volatile is Syndax Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Syndax Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: SNDX ($6.36) is trading below our estimate of fair value ($129.07)

Significantly Undervalued: SNDX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SNDX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SNDX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SNDX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SNDX is overvalued based on its PB Ratio (3.1x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Syndax Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

23.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SNDX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SNDX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SNDX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SNDX's revenue (85.6% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: SNDX's revenue (85.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: SNDX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Syndax Pharmaceuticals performed over the past 5 years?

-4.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SNDX is unprofitable, and losses have increased over the past 5 years at a rate of -4% per year.

Accelerating Growth: Unable to compare SNDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SNDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: SNDX has a negative Return on Equity (-118.31%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SNDX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SNDX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Syndax Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SNDX's short term assets ($85.8M) exceeds its short term liabilities ($17.5M)

Long Term Liabilities: SNDX's short term assets (85.8M) exceeds its long term liabilities (14.6M)


Debt to Equity History and Analysis

Debt Level: SNDX is debt free.

Reducing Debt: SNDX has no debt compared to 5 years ago when its debt to equity ratio was 2.5%.


Balance Sheet

Inventory Level: SNDX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SNDX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SNDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SNDX has sufficient cash runway for 1.253236 years if free cash flow continues to reduce at historical rates of -29.3% each year.


Next Steps

Dividend

What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SNDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SNDX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SNDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SNDX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SNDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Syndax Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Briggs Morrison (59yo)

4.3yrs

Tenure

US$2,080,513

Compensation

Dr. Briggs W. Morrison, M.D. serves as the Executive Partner MPM Capital. He joined MPM in 2015. He is the Chairman of Scientific Advisory Board at Cerenis Therapeutics Holding SA since May 2018. Dr. Morri ...


CEO Compensation Analysis

Compensation vs. Market: Briggs's total compensation ($USD2.08M) is about average for companies of similar size in the US market ($USD1.18M).

Compensation vs Earnings: Briggs's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.3yrs

Average Tenure

60.5yo

Average Age

Experienced Management: SNDX's management team is considered experienced (4.3 years average tenure).


Board Age and Tenure

3.3yrs

Average Tenure

57.5yo

Average Age

Experienced Board: SNDX's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: SNDX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$59,40011 Oct 19
Briggs Morrison
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares11,000
Max PriceUS$5.40
BuyUS$152,24313 May 19
Briggs Morrison
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares20,400
Max PriceUS$7.56
BuyUS$5,47525 Mar 19
Michael Meyers
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares1,112
Max PriceUS$4.93
BuyUS$95807 Nov 18
Michael Meyers
EntityIndividual
Role
Senior Key Executive
Chief Medical Officer
Shares200
Max PriceUS$4.79

Ownership Breakdown


Management Team

  • Rick Shea (67yo)

    CFO & Treasurer

    • Tenure: 2.7yrs
    • Compensation: US$13.00k
  • Ed Sausville

    • Tenure: 0yrs
  • Ronald Evans

    Co-Founder

    • Tenure: 3.3yrs
  • Michael Metzger (48yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$1.52m
  • Rich Heyman (62yo)

    Co-Founder

    • Tenure: 0yrs
  • Peter Ordentlich (50yo)

    Co-Founder & Chief Scientific Officer

    • Tenure: 14yrs
  • Michael Downes

    Co-Founder

    • Tenure: 0yrs
  • Briggs Morrison (59yo)

    CEO & Director

    • Tenure: 4.3yrs
    • Compensation: US$2.08m
  • Luke Albrecht

    General Counsel & Corporate Secretary

    • Tenure: 0yrs
  • Michael Meyers (68yo)

    Chief Medical Officer

    • Tenure: 4.2yrs
    • Compensation: US$1.05m

Board Members

  • Jay Lichter (57yo)

    Observer

    • Tenure: 0yrs
  • Keith Katkin (48yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$209.91k
  • Pierre Legault (58yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$223.16k
  • Dennis Podlesak (61yo)

    Chairman

    • Tenure: 10.8yrs
    • Compensation: US$245.16k
  • George Sledge (67yo)

    Member of Scientific Advisory Board

    • Tenure: 2.5yrs
    • Compensation: US$23.05k
  • Ronald Evans

    Co-Founder

    • Tenure: 3.3yrs
  • Michael Metzger (48yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$1.52m
  • Fabrice Egros (56yo)

    Director

    • Tenure: 6.1yrs
    • Compensation: US$199.66k
  • Briggs Morrison (59yo)

    CEO & Director

    • Tenure: 4.3yrs
    • Compensation: US$2.08m
  • Julie Brahmer

    Member of Scientific Advisory Board

    • Tenure: 3.8yrs

Company Information

Syndax Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Syndax Pharmaceuticals, Inc.
  • Ticker: SNDX
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$172.590m
  • Shares outstanding: 27.14m
  • Website: https://www.syndax.com

Number of Employees


Location

  • Syndax Pharmaceuticals, Inc.
  • 35 Gatehouse Drive
  • Building D
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1T3DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2016
SNDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2016

Biography

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III cli ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:26
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.